These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32794211)

  • 1. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB
    Morales P; Navarro G; Gómez-Autet M; Redondo L; Fernández-Ruiz J; Pérez-Benito L; Cordomí A; Pardo L; Franco R; Jagerovic N
    Chemistry; 2020 Dec; 26(68):15839-15842. PubMed ID: 32794211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
    Gado F; Ferrisi R; Polini B; Mohamed KA; Ricardi C; Lucarini E; Carpi S; Domenichini F; Stevenson LA; Rapposelli S; Saccomanni G; Nieri P; Ortore G; Pertwee RG; Ghelardini C; Di Cesare Mannelli L; Chiellini G; Laprairie RB; Manera C
    J Med Chem; 2022 Jul; 65(14):9918-9938. PubMed ID: 35849804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.
    Ortega-Gutiérrez S; López-Rodríguez ML
    Mini Rev Med Chem; 2005 Jul; 5(7):651-8. PubMed ID: 16026311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
    Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
    ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
    Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
    Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs.
    Feng Z; Alqarni MH; Yang P; Tong Q; Chowdhury A; Wang L; Xie XQ
    J Chem Inf Model; 2014 Sep; 54(9):2483-99. PubMed ID: 25141027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
    Pei Y; Mercier RW; Anday JK; Thakur GA; Zvonok AM; Hurst D; Reggio PH; Janero DR; Makriyannis A
    Chem Biol; 2008 Nov; 15(11):1207-19. PubMed ID: 19022181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal Structure of the Human Cannabinoid Receptor CB2.
    Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
    Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators.
    Yuan J; Jiang C; Wang J; Chen CJ; Hao Y; Zhao G; Feng Z; Xie XQ
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology of cannabinoid receptors.
    Abood ME
    Handb Exp Pharmacol; 2005; (168):81-115. PubMed ID: 16596772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.
    Tuccinardi T; Ferrarini PL; Manera C; Ortore G; Saccomanni G; Martinelli A
    J Med Chem; 2006 Feb; 49(3):984-94. PubMed ID: 16451064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
    Bhattacharjee H; Gurley SN; Moore BM
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1691-3. PubMed ID: 19230659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
    Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
    J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Binding Mechanisms for Allosteric Sodium Ion in Cannabinoid Receptors.
    Dutta S; Selvam B; Shukla D
    ACS Chem Neurosci; 2022 Feb; 13(3):379-389. PubMed ID: 35019279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex.
    Mnpotra JS; Qiao Z; Cai J; Lynch DL; Grossfield A; Leioatts N; Hurst DP; Pitman MC; Song ZH; Reggio PH
    J Biol Chem; 2014 Jul; 289(29):20259-72. PubMed ID: 24855641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.
    Zhang Y; Xie Z; Wang L; Schreiter B; Lazo JS; Gertsch J; Xie XQ
    Int Immunopharmacol; 2011 Sep; 11(9):1303-10. PubMed ID: 21539938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB
    Casajuana-Martin N; Navarro G; Gonzalez A; Llinas Del Torrent C; Gómez-Autet M; Quintana García A; Franco R; Pardo L
    J Chem Inf Model; 2022 Nov; 62(22):5771-5779. PubMed ID: 36302505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
    Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.